MEIP MEI Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MEIP

Price (delayed)

$3.56

Market cap

$23.72M

P/E Ratio

0.91

Dividend/share

N/A

EPS

$3.92

Enterprise value

$33.02M

MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in ...

Highlights
The EPS has soared by 169% YoY and by 32% from the previous quarter
MEIP's net income has surged by 169% year-on-year and by 32% since the previous quarter
The equity rose by 49% YoY but it fell by 14% QoQ
The company's quick ratio fell by 21% QoQ but it rose by 19% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.meipharma.com
Peers: LGND CRIS XOMA ARRY

Key stats

What are the main financial stats of MEIP
Market
Shares outstanding
6.66M
Market cap
$23.72M
Enterprise value
$33.02M
Valuations
Price to earnings (P/E)
0.91
Price to book (P/B)
0.46
Price to sales (P/S)
0.36
EV/EBIT
1.26
EV/EBITDA
1.18
EV/Sales
0.49
Earnings
Revenue
$66.75M
EBIT
$26.16M
EBITDA
$28.01M
Free cash flow
-$43.82M
Per share
EPS
$3.92
Free cash flow per share
-$6.58
Book value per share
$7.66
Revenue per share
$10.02
TBVPS
$10.69
Balance sheet
Total assets
$71.26M
Total liabilities
$20.23M
Debt
$11.67M
Equity
$51.03M
Working capital
$49.75M
Liquidity
Debt to equity
0.23
Current ratio
6.17
Quick ratio
5.88
Net debt/EBITDA
0.33
Margins
EBITDA margin
42%
Gross margin
100%
Net margin
39.2%
Operating margin
33.6%
Efficiency
Return on assets
28.1%
Return on equity
48.3%
Return on invested capital
30.2%
Return on capital employed
42.4%
Return on sales
39.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MEIP stock price

How has the MEI Pharma stock price performed over time
Intraday
2.89%
1 week
24.48%
1 month
24.48%
1 year
-53.03%
YTD
-38.62%
QTD
22.34%

Financial performance

How have MEI Pharma's revenue and profit performed over time
Revenue
$66.75M
Gross profit
$66.75M
Operating income
$22.44M
Net income
$26.16M
Gross margin
100%
Net margin
39.2%
MEIP's net income has surged by 169% year-on-year and by 32% since the previous quarter
MEI Pharma's net margin has surged by 161% YoY and by 44% QoQ
The operating income has soared by 154% YoY and by 41% from the previous quarter
The operating margin has soared by 147% YoY and by 53% from the previous quarter

Growth

What is MEI Pharma's growth rate over time

Valuation

What is MEI Pharma stock price valuation
P/E
0.91
P/B
0.46
P/S
0.36
EV/EBIT
1.26
EV/EBITDA
1.18
EV/Sales
0.49
The EPS has soared by 169% YoY and by 32% from the previous quarter
The stock's price to book (P/B) is 85% less than its 5-year quarterly average of 3.1 and 49% less than its last 4 quarters average of 0.9
The equity rose by 49% YoY but it fell by 14% QoQ
MEIP's P/S is 96% below its 5-year quarterly average of 9.3 and 40% below its last 4 quarters average of 0.6
MEIP's revenue is up by 14% YoY but it is down by 8% QoQ

Efficiency

How efficient is MEI Pharma business performance
The ROS has soared by 161% YoY and by 44% from the previous quarter
The ROE has soared by 155% YoY and by 22% QoQ
MEI Pharma's ROIC has soared by 138% YoY and by 9% from the previous quarter
MEIP's return on assets has surged by 54% since the previous quarter

Dividends

What is MEIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MEIP.

Financial health

How did MEI Pharma financials performed over time
The total liabilities has plunged by 80% YoY but it has grown by 6% from the previous quarter
The total assets has declined by 47% year-on-year and by 9% since the previous quarter
MEI Pharma's debt is 77% lower than its equity
The equity rose by 49% YoY but it fell by 14% QoQ
MEI Pharma's debt to equity has decreased by 39% YoY but it has increased by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.